BioLife Solutions

BLFS

Market cap $1.04B

The average of price targets set by Wall Street analysts indicates a potential upside of 70.8% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The heavy selling pressure might have exhausted for BioLife Solutions (BLFS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

BioLife Solutions has executed a successful turnaround by refocusing on core biopreservation media and vials, divesting non-core assets. BLFS expects 17–20% revenue growth in FY26, positive GAAP net income, and mid-60s gross margins, supported by dominant CGT market share. Strategic acquisitions like PanTHERA and partnerships such as QKine are set to drive ARPU expansion and next-gen product launches by late 2026.

The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BioLife Solutions, Inc. (BLFS) Q4 2025 Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.01 per share a year ago.

Fourth quarter 2025  revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year 2025 revenue of $96.2 million, up 29% year-over-year GAAP gross margin of 63% and non-GAAP adjusted gross margin of 64% for the fourth quarter GAAP net income of $2.1 million  or $0.04 per share and adjusted EBITDA of $6.9 million, or 28% of total revenue for the fourth quarter Expects 2026 revenue growth of $112.5 million  to $115.0 million, up 17%-20% over 2025 Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.

BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2025 fourth quarter and full year financial results will be released on February 26, 2026.

BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing.

The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.